Compare GTY & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GTY | ORKA |
|---|---|---|
| Founded | 1955 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | N/A | N/A |
| Metric | GTY | ORKA |
|---|---|---|
| Price | $28.07 | $31.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $31.80 | ★ $48.20 |
| AVG Volume (30 Days) | 370.6K | ★ 440.6K |
| Earning Date | 10-22-2025 | 11-12-2025 |
| Dividend Yield | ★ 6.83% | N/A |
| EPS Growth | ★ 10.25 | N/A |
| EPS | ★ 1.28 | N/A |
| Revenue | ★ $214,194,000.00 | N/A |
| Revenue This Year | $6.23 | N/A |
| Revenue Next Year | $8.82 | N/A |
| P/E Ratio | $22.24 | ★ N/A |
| Revenue Growth | ★ 8.17 | N/A |
| 52 Week Low | $25.39 | $5.49 |
| 52 Week High | $32.50 | $32.28 |
| Indicator | GTY | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 48.53 | 60.77 |
| Support Level | $28.31 | $27.84 |
| Resistance Level | $28.79 | $31.35 |
| Average True Range (ATR) | 0.43 | 1.96 |
| MACD | -0.03 | -0.21 |
| Stochastic Oscillator | 38.10 | 89.55 |
Getty Realty Corp is the real estate investment trust in the U.S. specializing in the acquisition, financing, and development of convenience, automotive, and other single tenant retail real estate. The company's portfolio includes convenience stores, car washes, automotive service centers (gasoline and repair, oil and maintenance, tire and battery, collision), automotive parts retailers, and certain other freestanding retail properties, including drive-thru quick service restaurants. It generates majority of the revenue in the form of rental income.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.